Processa Pharmaceuticals Inc (OQ:PCSA)

Nov 16, 2020 12:47 pm ET
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical...
Nov 12, 2020 05:01 pm ET
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update
via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the...
Nov 05, 2020 09:15 am ET
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, is pleased...
Nov 03, 2020 09:20 am ET
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical need...
Oct 13, 2020 09:30 am ET
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, is pleased to...
Oct 06, 2020 04:05 pm ET
Processa Pharmaceuticals Closes $19.2 Million Public Offering
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a...
Oct 02, 2020 06:00 am ET
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of...
Aug 27, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMOR
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a contingent precedent exclusive licensing agreement with Elion Oncology, Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is...
Aug 20, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean based company, to license in YH12852. YH12852 is a small molecule drug in development for the...
Jun 01, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has signed an agreement with Aposense, LTD. to license in the patent rights and the know-how to develop and commercialize their next generation irinotecan cancer drug, ATT-11T....
Mar 30, 2020 04:00 pm ET
PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), announced the successful completion of their meeting with the U.S. Food and Drug Administration (FDA) for PCS499, its investigational product targeting the treatment of Necrobiosis Lipoidica (NL)....
Mar 17, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced the completion of its...
Mar 05, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that they...
Feb 25, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS PROVIDES SHAREHOLDER UPDATE
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides a year-end review and an...
Feb 13, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS APPOINTS GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS
Processa Pharmaceuticals, Inc. (OTC: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that Geraldine Pannu was...
Dec 20, 2019 04:10 pm ET
PROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that it will...
Dec 04, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS PROVIDES AN UPDATE ON POSITIVE RESULTS FROM PCS-499 PHASE 2 TRIAL
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update on its...
Sep 03, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES THE LICENSING OF AN ANTI-FIBROTIC, ANTI-INFLAMMATORY DRUG FOR THE TREATMENT OF MULTIPLE UNMET MEDICAL NEED CONDITIONS
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that they have...
Aug 26, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the last patient...
Jul 15, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update for its...
May 20, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE JEFFRIES 2019 GLOBAL HEALTHCARE CONFERENCE ON FRIDAY, JUNE 7TH, 2019
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that it will be...
Mar 11, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE COWEN CONFERENCE ON WEDNESDAY - MARCH 13, 2019
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that it will be...
Jan 29, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the dosing of the...
Jan 09, 2019 09:00 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that the American...
Dec 06, 2018 09:00 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that its stock...
Oct 02, 2018 09:00 am ET
Processa Pharmaceuticals Receives FDA Clearance Of IND To Begin Phase 2 Clinical Development Of PCS-499 In Necrobiosis Lipoidica Patients
HANOVER, Md., Oct. 2, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Processa clearance to proceed with a Phase 2 clinical trial of PCS-499 in patients with Necrobiosis Lipoidica (NL) under a recently submitted Investigational New Drug (IND) application. ...
Sep 10, 2018 09:00 am ET
Processa Pharmaceuticals Appoints James Stanker As Chief Financial Officer
HANOVER, Md., Sept. 10, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that James Stanker was appointed Chief Financial Officer on September 5, 2018....
Jun 22, 2018 09:00 am ET
Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)
HANOVER, Md., June 22, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to its leading clinical compound PCS499 for treatment of Necrobiosis Lipoidica (NL)....
Jun 01, 2018 12:00 pm ET
Processa Pharmaceuticals Raises $6.88 Million From Private Placements
HANOVER, Md., June 1, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA) is pleased to announce it has raised a total of $6.88 million from private placements.  The $6.88 million raise consists of 3 investments described below: $2.50 million from the first tranche of an on-going private placement; a private placement for funding of clinical trials of $1.80 million; and a mandatory conversion of 8% Senior Notes totaling $2.58 million.  For these 3 private placements, agent fees and estimated expenses payable by the Company are associated with the gross proceeds....
Mar 21, 2018 09:00 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS
HANOVER, MD, March 21, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet’s exercising of...
Mar 21, 2018 09:00 am ET
Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions
HANOVER, Md., March 21, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet's exercising of the exclusive option to license in CTP-499 from Concert Pharmaceuticals, Inc.  ...
Mar 02, 2018 08:00 am ET
Processa Pharmaceuticals Announces Attendance at 2018 ROTH Conference
HANOVER, Md., March 2, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. ("Processa") (OTC PINK: PCSA), will attend and participate in meetings at the 30th annual ROTH Conference March 11-14, 2018 at the Ritz Carlton, Laguna Niguel in Orange County, CA. ...
Dec 11, 2017 08:03 am ET
Processa Pharmaceuticals Announces Reverse Stock Split and Launches New Website
HANOVER, Md., Dec. 11, 2017 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (the "Processa") (OTC PINK: PCSA), formed from the merger of Promet Therapeutics and Heatwurx Inc., is an emerging clinical stage biotech company focused on the development of drugs for the treatment of high unmet medical need conditions.  Processa announced today that the Financial Industry Regulatory Association (FINRA) confirmed the below listed corporate actions requested by Processa:...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.